166 related articles for article (PubMed ID: 32379970)
1. Loop Grafting between Similar Local Environments for Fc-Silent Antibodies.
Lešnik S; Hodošček M; Podobnik B; Konc J
J Chem Inf Model; 2020 Nov; 60(11):5475-5486. PubMed ID: 32379970
[TBL] [Abstract][Full Text] [Related]
2. Mouse IgG2c Fc loop residues promote greater receptor-binding affinity than mouse IgG2b or human IgG1.
Falconer DJ; Barb AW
PLoS One; 2018; 13(2):e0192123. PubMed ID: 29408873
[TBL] [Abstract][Full Text] [Related]
3. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
4. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
Arduin E; Arora S; Bamert PR; Kuiper T; Popp S; Geisse S; Grau R; Calzascia T; Zenke G; Kovarik J
Mol Immunol; 2015 Feb; 63(2):456-63. PubMed ID: 25451975
[TBL] [Abstract][Full Text] [Related]
5. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
6. Integrin binding human antibody constant domains--probing the C-terminal structural loops for grafting the RGD motif.
Traxlmayr MW; Wozniak-Knopp G; Antes B; Stadlmayr G; Rüker F; Obinger C
J Biotechnol; 2011 Sep; 155(2):193-202. PubMed ID: 21771617
[TBL] [Abstract][Full Text] [Related]
7. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
8. Structural mechanism of high affinity FcγRI recognition of immunoglobulin G.
Lu J; Sun PD
Immunol Rev; 2015 Nov; 268(1):192-200. PubMed ID: 26497521
[TBL] [Abstract][Full Text] [Related]
9. Synthetic peptides from mouse Fc receptor (MoFc gamma RII) that alter the binding of IgG to MoFc gamma RII.
Goldsmith EB; Erickson BW; Thompson NL
Biochemistry; 1997 Jan; 36(4):952-9. PubMed ID: 9020795
[TBL] [Abstract][Full Text] [Related]
10. Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.
Chen TF; Sazinsky SL; Houde D; DiLillo DJ; Bird J; Li KK; Cheng GT; Qiu H; Engen JR; Ravetch JV; Wittrup KD
J Mol Biol; 2017 Aug; 429(16):2528-2541. PubMed ID: 28694069
[TBL] [Abstract][Full Text] [Related]
11. Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.
Ju MS; Na JH; Yu YG; Kim JY; Jeong C; Jung ST
Mol Immunol; 2015 Oct; 67(2 Pt B):350-6. PubMed ID: 26153451
[TBL] [Abstract][Full Text] [Related]
12. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.
Roberts JT; Barb AW
J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439
[TBL] [Abstract][Full Text] [Related]
13. Identification of the IgG binding site of the human low affinity receptor for IgG Fc gamma RII. Enhancement and ablation of binding by site-directed mutagenesis.
Hulett MD; Witort E; Brinkworth RI; McKenzie IF; Hogarth PM
J Biol Chem; 1994 May; 269(21):15287-93. PubMed ID: 8195166
[TBL] [Abstract][Full Text] [Related]
14. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
Pollastrini J; Dillon TM; Bondarenko P; Chou RY
Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
[TBL] [Abstract][Full Text] [Related]
15. The IgG binding site of human FcgammaRIIIB receptor involves CC' and FG loops of the membrane-proximal domain.
Tamm A; Kister A; Nolte KU; Gessner JE; Schmidt RE
J Biol Chem; 1996 Feb; 271(7):3659-66. PubMed ID: 8631977
[TBL] [Abstract][Full Text] [Related]
16. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
17. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
18. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.
Caaveiro JM; Kiyoshi M; Tsumoto K
Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522
[TBL] [Abstract][Full Text] [Related]
19. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
20. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
